

**FORM 51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company**

Abattis Biocenticals Corp.  
Suite 1000, 355 Burrard Street  
Vancouver, BC V6C 1N5

**Item 2. Date of Material Change**

December 3, 2013

**Item 3. News Release**

A news release dated and disseminated December 3, 2013 at Vancouver, British Columbia, through Canada Stockwatch, Market News Publishing, CNSX Markets and SEDAR.

**Item 4. Summary of Material Change**

Abattis announced the resignation of a director.

**Item 5. Full Description of Material Change**

See news release, a copy of which is attached hereto.

**Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

Not applicable.

**Item 8. Executive Officer**

Michael Withrow, President & CEO  
Telephone: 604.538.6650  
Email: mike.withrow@abattis.com

**Item 9. Date of Report**

December 10, 2013

---

## ABATTIS ANNOUNCES RESIGNATION OF A DIRECTOR

Vancouver, BC – December 3, 2013 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (CNSX: FLU), announces the resignation of Mr. Nick Brusatore as a Director of the Company effective November 29, 2013. Mr. Mike Withrow, Chairman of the Board of the Directors on behalf of the Company, thanks Mr. Brusatore for his service and contribution to the Company and stated, "This is positive for both Abattis and Vertical Designs as it will enable Mr. Brusatore to maintain his focus and energies on further advancing the Vertical Growing Equipment technologies Abattis owns the World Wide Licence to in the areas of Pharmaceutical, Nutraceutical, Cosmeceuticals and Wellness."

### About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal marijuana in North America. The company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions by supplying and partnering with companies to employ its vertical growing systems, extraction equipment/technology, and strategic marketing support to licensed growers and dispensaries. The company also has an extensive pipeline of high-quality products and Intellectual Property for the rapidly expanding botanical drug market. For more information, visit the Company's website at [www.abattis.com](http://www.abattis.com).

### ON BEHALF OF THE BOARD

"Mike Withrow"

Mike Withrow  
President & CEO

For information please contact:

**Mike Withrow**  
P: 778.896.6536  
[www.abattis.com](http://www.abattis.com)

*Neither the CNSX Exchange nor its regulations services accepts responsibility  
for the adequacy or accuracy of this release.*